Reports From National Arthritis Meeting
Dr. Shiel Gives Perspectives Of Interest On Vasculitis From 2001 Annual
Scientific Meeting Of The American College Of Rheumatology
Below are perspectives on key reports presented at the recent national
meeting of the American College of Rheumatology:
Introduction
Vasculitis is a general term for a group of
uncommon diseases that feature inflammation of the blood vessels. The blood
vessels of the body are referred to as the vascular system. The blood vessels
are composed of arteries, which pass oxygen-rich blood to the tissues of the
body, and veins, which return oxygen-depleted blood from the tissues to the
lungs for oxygen. Vasculitis is characterized by inflammation in and damage to
the walls of the various blood vessels.
Each of the vasculitis diseases (also, as a
group, referred to as vasculitides) is defined by certain patterns of
distribution of blood vessel involvement, particular organ involvement, and
laboratory test abnormalities. The diagnosis of vasculitis is confirmed by a
biopsy of involved tissue or angiography. The treatment is directed toward
decreasing the inflammation of the arteries and improving the function of
affected organs.
Below are perspectives on key reports on
vasculitis diseases presented at the recent national meeting of the American
College of Rheumatology:
Wegener's Granulomatosis
Wegener's granulomatosis classically involves
inflammation of the arteries that supply blood to the tissues of the lungs, the
nasal passages (sinuses), and the kidneys. There are "incomplete"
forms of the disease that only involve one of these areas. Symptoms of Wegener's
granulomatosis include fatigue, weight loss, fevers, shortness of breath, bloody
sputum, joint pains, and sinus inflammation (sinusitis). Nasal ulcerations and
even blood nasal discharge can occur. Other areas of the body that can also
become inflamed in patients with Wegener's granulomatosis include the eyes, the
nerves (neuropathy), the middle ear (otitis media), and the skin, which results
in skin nodules or ulcers.
Cytoxan (cyclophosphamide) that is taken by mouth
with prednisone until the disease is in remission and then switched to
methotrexate for 2 years and tapered off was effective and less toxic than the
traditional long-term Cytoxan treatment.
Dr. Shiel's Perspective: This was an important
paper presented at this meeting. Methotrexate has recently been introduced as a
drug for Cytoxan treatment failures. I have several patients doing very well on
it for this purpose in my practice. The significance of this paper is twofold.
First, while Cytoxan is very effective, it is also toxic. It now appears that
Cytoxan will not be necessary in order to maintain long-term remission and that
doctors can convert to the less toxic methotrexate for maintenance. Secondly,
the report also demonstrates that methotrexate can eventually be tapered off
entirely after 2 years. This is good news for patients with Wegener's
granulomatosis.